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Abstract
A large number of neuroanatomical, neurophysiologic, and neurochemical mechanisms are thought to contribute to the
development and maintenance of neuropathic pain. However, mechanisms responsible for neuropathic pain have not been
completely delineated. It has been demonstrated that neuropeptide galanin (Gal) is upregulated after injury in the dorsal
root ganglion (DRG) and spinal dorsal horn (SDH) where it plays a predominantly antinociceptive role. In the present study,
sciatic nerve-pinch injury rat model was used to determine the effects of exogenous Gal on the expression of the Gal and its
receptors (GalR1, GalR2) in DRG and SDH, the alterations of pain behavior, nerve conduction velocity (NCV) and morphology
of sciatic nerve. The results showed that exogenous Gal had antinociceptive effects in this nerve-pinch injury induced
neuropathic pain animal model. It is very interesting that Gal, GalR1 and GalR2 change their expression greatly in DRG and
SDH after nerve injury and intrathecal injection of exougenous Gal. Morphological investigation displays a serious damage
after nerve-pinch injury and an amendatory regeneration after exogenous Gal treatment. These findings imply that Gal, via
activation of GalR1 and/or GalR2, may have neuroprotective effects in reducing neuropathic pain behaviors and improving
nerve regeneration after nerve injury.
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Introduction
Damages to the nervous system are the primarily cause of
neuropathic pain [1]. A large number of neuroanatomical,
neurophysiologic, and neurochemical mechanisms are thought to
contribute to the development and maintenance of neuropathic
pain [2]. Neuropathic pain is a severe health problem for which
there is a lack of effective therapy [3]. Even in present day pain
therapy, neuropathic pain remains a challenge for clinicians to
treat and a challenge for researchers to investigate [4]. Mecha-
nisms responsible for neuropathic pain have not been completely
delineated. Different animal models have been developed to
mimic neuropathic pain. Sciatic nerve-pinch injury is a reliable
animal model for evaluating pain behavior [5].
Dorsal root ganglion (DRG) is anatomically discrete peripheral
nervous system (PNS) structure located on the dorsal root of each
spinal nerve immediately adjacent to the spinal cord. Each
ganglion contains the cells bodies of sensory neurons of
pseudounipolar structure, the stem axons of which send processes
peripherally into the corresponding spinal nerve and centrally into
the spinal cord where they synapse on the neurons in the spinal
cord and brainstem of central nervous system (CNS). DRG is
recognized as one of the organs which are damaged in peripheral
sensory neuropathic pain states [6]. It has been suggested that the
spinal cord is a site of amplified sensory processing in neuropathic
pain states [7,8]. Spinal dorsal horn (SDH) is important in
mediating nociceptive signaling [9–12]. It has been well recog-
nized that nerve lesion induces change of gene and protein
expression of neuropeptides and receptors in DRG and SDH
which correspond to induced neuropathic pain [13,14].
Neurotrophic peptide galanin (Gal) has been shown to be
effective in preventing or reversing neuropathic pain in animal
models [15,16]. Gal, a 29-amino-acid neuropeptide in most
species (30-amino-acid in human), is widely expressed in both the
PNS and CNS and is involved in many diverse biological functions
including nociception, developmental and trophic effects [17–21].
Gal is present in a small population of DRG neurons and is
thought to play only a minor role in nociception under normal
conditions. However, there is a substantial data set that
demonstrates Gal is increased after injury in the DRG and spinal
cord where it plays a predominantly antinociceptive role in
addition to being neuroprotective and pro-regenerative [22].
These data led us to speculate that Gal might play a paregoric and
trophic role in nerve injury-induced neuropathic pain model.
Hence, it is important to discover whether exogenous Gal
improves pain behaviour, nerve conduction velocity (NCV) and
axonal morphology after nerve injury. In the present study, sciatic
nerve-pinch injury rat model was used to determine the effects of
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(GalR1, GalR2) in DRG and SDH, the alterations of pain
behavior, NCV and morphology of sciatic nerve.
Materials and Methods
Ethics Statement
All animals were cared for in compliance with the Guide for the
Care and Use of Laboratory Animals (revised 1996; http://www.
nap.edu). All procedures described herein were reviewed by and
had prior approval by the Ethical Committee for Animal
Experimentation of the Shandong University. All surgery was
performed under anesthesia, and all efforts were made to minimize
suffering.
Animal and catheter implantation
All preparations utilized male rats (300 g,350 g) taken from
the breeding colony of Wistar rats maintained in the Experimental
Animal Center at Shandong University of China. All animals were
housed in plastic cages with a normal light-dark cycle keeping
room temperature 20uC,25uC and allowed free access to chow
and water. The rats were anesthetized with of 10% chloral hydrate
(300 mg/kg) intraperitoneally (i.p.) before catheter implantation.
A sterile polyethylene catheter (PE-10, 15.0 cm length) (Instech
Laboratories Incorporation, Plymouth Meeting, PA, USA) was
inserted into the subarachnoid space through an incision in the
gap between the lumbar (L)6 and sacral (S)1 vertebra. The tip of
the catheter was implanted between L4 and L5 DRG level. Three
days after implantation, the correct catheter placement was
confirmed by intrathecally injecting 10 ml 2% lidocaine. Only
the rat showing a reversible paralysis of the hind paws within
30 seconds following the lidocaine injection were considered to be
catheterized successfully.
Sciatic nerve-pinch injury pain animal model
After the baseline pain behavior tests were finished, the
successfully catheterized rats were anesthetized with 10% chloral
hydrate. Bilateral sciatic nerve were exposed and pinched for
3 seconds with a microsurgery clamp (0.3 mm tip) at the point
where the nerve came across the adductor brevis muscle. The
surgical procedures of the sham-operated animals were same as
the operated animals except nerve pinch.
Animal groups and intrathecal drug administration
Sixty-three rats with successful catheter implantation were
randomly divided into 3 groups (21 rats in each group). Group 1:
Animals with sciatic nerve-pinch injury were treated with vehicle
solution (i.t.). Group 2: Animals with sciatic nerve-pinch injury
were treated with Gal (3 mg/day, i.t.) (Tocris Bioscience, Bristol,
UK). Group 3: The sham-operated control animals were treated
with vehicle solution (i.t.). At the day 8, 16, and 24 (each time
point 7 rats in each group) after sciatic nerve-pinch injury, animals
were processed for NCV measurement after anesthesia with 10%
chloral hydrate. After that, the L4-5 DRG and the corresponding
SDH and sciatic nerve explants (2 mm distal to the pinch injury
point) were surgically harvested for different experimental
examination.
Gal was dissolved in artificial cerebrospinal fluid (ACSF) at
0.3 mg/ml. The composition of ACSF (pH7.4) is as follows (mmol/
L): NaCl, 138.6; KCl, 3.35; CaCl2?2H2O, 1.26; MgCl2?6H2O,
1.16; NaH2PO4?2H2O, 0.58; NaHCO3, 21.0; glucose, 10.0 [23].
Evaluation of mechanical and thermal hyperalgesia
The threshold responses to mechanical and thermal stimuli
were tested daily on both hind paws with Von Frey filaments
(BME-403, Chinese academy of medical sciences institute of
biomedical engineering) and a plantar analgesia tester (BME-
400C, Chinese academy of medical sciences institute of biomedical
engineering), respectively.
Mechanical hyperalgesia was determined by 50% withdrawal
thresholds to mechanical stimuli applying to the hind paws. All
rats involved in this test were acclimated in a clear plastic cage
with a wire mesh bottom individually for 15 minutes. A series of
filaments (0.1, 0.5, 1.0, 3.0, 3.8, 5.0, 8.2, and 14.6 g), starting with
3.0 g, were used serially to stimulate the central region of the
plantar surface of the rat’s hind paws in ascending or descending
order of stiffness depending on the foot withdrawal response of the
rats. The filament was applied with a pressure that was just
sufficient to bend the filament for 5 seconds. A brisk withdrawal of
the hind paw was recorded as a positive response. The interval
between the two stimuli was at least 5 seconds. Both hind paws
were tested twice for average. The score was cut off at a force of
14.6 g to prevent the hind paw from injury. The 50% threshold to
mechanical stimuli was interpolated according to the sequence of
positive and negative scores.
Thermal hyperalgesia was determined as the withdrawal latency
to a noxious radiant heat stimulus. Each rat was placed in a
transparent plastic chamber (15620630 cm) on a thin glass
platform maintained at 30uC. All animals involved in this test were
acclimated to the environment for 15 minutes before testing. A
mobile radiant heat lamp generated by a high intensity light bulb
(10 W) was then positioned directed underneath the targeted hind
paw. The mean withdrawal latency was determined by 4 tests
(after excluding the minimal and maximal values). A cutoff of
20 seconds was used to avoid tissue injury.
NCV determination
Both motor NCV (MNCV) and sensory NCV (SNCV) of the rat
sciatic nerve was determined by a Keypoint electromyography
(EMG)/evoked potentials (EP) systems (Dantec, Copenhagen,
Denmark). Briefly, after anesthesia with 10% chloral hydrate, rat
was placed on a heating mat to maintained rectal temperature at
38uC. Sciatic nerve conduction was performed by stimulating
proximally at the sciatic notch which is almost 0.7 cm above the
pinch point and distally at he Achilles tendon with bipolar
electrodes. The latencies of M-wave (compound muscle action
potential) and H-reflex were recorded via a needle electrode from
the second interosseous muscle of the hind paw. The MNCV and
SNCV were calculated by subtracting the distal and proximal
latencies, and the result was divided into the distance between the
two stimulating points. The velocities were recorded as meters per
second.
Real time-PCR analysis of mRNAs for Gal, GalR1, and
GalR2
At the designed experimental time point, the L4-5 DRG and the
corresponding SDH of the rats were surgically harvested. The
mRNA levels of Gal, GalR1, and GalR2 in L4-5 DRG and the
corresponding SDH were analyzed by real time-PCR. The
expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA was also determined as an internal control.
Total RNA from DRG and SDH tissues was isolated by TRIzol
(Invitrogen, Grand Island, NY). cDNA was synthesized using
cDNA synthesis kit (Fermentas, EU) according to the manufac-
turer’s instructions. The synthetic oligonucleotide primer sequenc-
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TGC AAC CCT GTC AGC CAC TC -39 (coding sense) and 59-
TGT CGC TAA ATG ATC TGT GGT TGT C -39 (coding
antisense). GalR1 59- AGG CTT ACG TGG TGT GCA CTT
TC -39 (coding sense) and 59- GCC ATG ATA TGC CAA ATA
CCA CAA -39 (coding antisense). GalR2 59- CAT CGT GGC
GGT GCT TTT -39 (coding sense) and 59- AGC GGG AAG
CGA CCA AAC -39 (coding antisense). GAPDH 59- GGC ACA
GTC AAG GCT GAG AAT G -39 (coding sense) and 59- ATG
GTG GTG AAG ACG CCA GTA -39 (coding antisense).
The amplification was conducted in a volume of 25 ml
containing 12.5 ml of Maxima SYBR Green qPCR Maxter Mix
(26) (Fermentas, EU), with 0.3 mmol/L forward and reverse
primers, 2 ml cDNA. Real time RT-PCR was carried out using the
eppendorf Realplex PCR system (Eppendorf, Hamburg, Ger-
many). PCR cycle conditions were as follows: activated at 95uC for
10 min, followed by amplification and quantification 40 cycles at
95uC for 15 s, 60uC for 30 s and 72uC for 30 s. A comparative
cycle of threshold fluorescence (Ct) method was used and the
relative transcript amount of the target gene was normalized to
that of GAPDH using the 2
2DDCt method based on a previous
study [24]. The final results of real time-PCR were expressed as
the ratio of mRNA of control.
Western blot assay of Gal, GalR1, and GalR2
At the designed experimental time point, the L4-5 DRG and the
corresponding SDH of the rats were surgically harvested. The
levels of Gal, GalR1, and GalR2 in L4-5 DRG and the
corresponding SDH were analyzed by Western blot assay. The
expression of b-actin was also determined as an internal control.
The DRG and SDH tissues were homogenized in 10 mmol/L
Tris homogenization buffer (pH 7.4) with protease inhibitors. The
samples were centrifuged at 10,000 g for 10 minutes and the
supernatant collected for Western blot assay. After determining
the protein concentrations of the supernatants (BCA method,
standard: BSA), 50 mg protein of each sample was loaded onto the
10% SDS gel, separated by electrophoresis and transferred to
nitrocellulose membrane. The membranes were blocked in
blocking buffer (5% nonfat milk) for 2 hours at room temperature,
and then were incubated with goat anti-Gal polyclonal IgG (1:500,
Santa Cruz Biotechnology), goat anti-GalR1 polyclonal IgG
(1:500, Santa Cruz Biotechnology), goat anti-GalR2 polyclonal
IgG (1:500, Santa Cruz Biotechnology) or mouse anti-b-actin
monoclonal IgG (1:1000, Santa Cruz Biotechnology) overnight at
4uC. After being washed three times for 10 minutes with washing
solution, the membranes were incubated with rabbit anti-goat
IgG-HRP (1:4000, Santa Cruz Biotechnology) or goat anti-mouse
IgG-HRP (1:4000, Santa Cruz Biotechnology). The immunore-
active bands were visualized by an ECL Western blotting
detection kit (Billerica) on light sensitive film. The films were
scanned and the images were analyzed quantitatively by using an
ImagJ 1.39 u image analysis software. The protein levels of Gal,
GalR1, and GalR2 were expressed as the ratio of control.
Morphological observation
At the conclusion of the experiments, sciatic nerve explants
(2 mm distal to the pinch injury point) were fixed in a
4%paraformaldehyde/3%glutaraldehyde solution for 30 minutes
at 4uC. The samples were postfixed in 1% osmium tetroxide in
0.1 mol/L phosphate buffer (PB) for 2 hours at 4uC and
embedded in Epon for 72 hours at 60uC. For toluidine blue
staining, transverse semi-thin sections (1 mm) of sciatic nerve were
cut with an ultramicrotome (Leica EM UC6), stained with 0.5%
toluidine blue and observed under a light microscope (Nikon
Eclipse 80i, Japan). For ultrastructural observation, ultra-thin
sections (70 nm) of sciatic nerve were processed for electron
microscopy and negatively stained with uranyl acetate and lead
citrate and examined with a JEOL-1400 transmission electron
microscope (TEM).
Statistical analysis
Data are expressed as mean 6 SD. The normal distribution of
all data was verified. If normality test is fail, the data were analyzed
with non-parametric test. If normality test is pass, statistical
analysis was evaluated with SPSS software by one-way ANOVA
followed by the Student-Newman-Keuls test for significance to
compare the differences among various groups. t test was used for
analysis of two independent samples. Significance was determined
as P,0.05.
Results
Effects of exogenous Gal on pain behaviour after sciatic
nerve-pinch injury
Sciatic nerve-pinch injury caused mechanical and thermal
hyperalgesia. The mechanical threshold decreased significantly
after sciatic nerve-pinch injury from day 1 to day 22. The
mechanical threshold recovered to normal baseline at day 23 after
sciatic nerve-pinch injury (Fig. 1). The thermal threshold
decreased significantly after sciatic nerve-pinch injury from day
2 to day 21. The thermal threshold recovered to normal baseline
at day 22 after sciatic nerve-pinch injury (Fig. 2). Administration of
Gal for sciatic nerve-pinch injured rats could substantially relieve
pain and shorten recovery time of pain behavior. Gal adminis-
tration increased mechanical threshold significantly after sciatic
nerve-pinch injury from day 10 to day 22 as compared with that in
sciatic nerve-pinched animals without Gal treatment. The
mechanical threshold recovered to normal baseline at day 20
after sciatic nerve-pinch injury with Gal treatment (Fig. 1). Gal
administration increased thermal threshold significantly after
sciatic nerve-pinch injury from day 4 to day 20 as compared with
that in sciatic nerve-pinched animals without Gal treatment. The
thermal threshold recovered to normal baseline at day 17 after
sciatic nerve-pinch injury with Gal treatment (Fig. 2). The
mechanical and thermal thresholds showed no significant differ-
ence between different experimental time in sham-operated
control animals (Fig. 1, Fig. 2).
Effects of exogenous Gal on NCV after sciatic nerve-pinch
injury
Both MNCV and SNCV decreased significantly after sciatic
nerve-pinch injury at day 16 and 24 (only few rats showing
myoelectricity reaction at day 8, data not shown) as compared
with that in sham-operated control animals. Gal administration
improved MNCV and SNCV significantly after sciatic nerve-
pinch injury at day 16 and 24 as compared with that in sciatic
nerve-pinched animals without Gal treatment (Fig. 3).
Expression of mRNAs for Gal, GalR1, and GalR2 in DRG
and SDH
Gal mRNA levels increased significantly in DRG and SDH
after sciatic nerve-pinch injury at day 8, 16, and 24 as compared
with that in sham-operated control animals. Gal administration
decreased Gal mRNA levels in DRG, but not SDH, after sciatic
nerve-pinch injury at day 8, 16, and 24 as compared with that in
sciatic nerve-pinched animals without Gal treatment at the same
experimental time point (Fig. 4A, B).
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sciatic nerve-pinch injury at day 8, 16, and 24 as compared with
that in sham-operated control animals. Gal administration
decreased GalR1 mRNA levels in DRG after sciatic nerve-pinch
injury at day 8, 16, and 24 as compared with that in sciatic nerve-
pinched animals without Gal treatment at the same experimental
time point (Fig. 4C). GalR1 mRNA levels increased significantly in
SDH after sciatic nerve-pinch injury at day 8, 16, and 24 as
compared with that in sham-operated control animals. Gal
administration decreased GalR1 mRNA levels in SDH after
sciatic nerve-pinch injury at day 8, 16, and 24 as compared with
that in sciatic nerve-pinched animals without Gal treatment and in
sham-operated control animals (Fig. 4D).
GalR2 mRNA levels increased significantly in DRG and SDH
after sciatic nerve-pinch injury at day 8, 16, and 24 as compared
with that in sham-operated control animals. Gal administration
did not have significant effects on GalR2 mRNA expression in
DRG and SDH after sciatic nerve-pinch injury as compared with
that in sciatic nerve-pinched animals without Gal treatment at the
same experimental time point (Fig. 4E, F).
Figure 1. The mechanical threshold alterations with different treatment from day 0 to day 24. The data are presented as means 6 SD
(n=7). *P,0.05 vs. control, **P,0.01 vs. control, ***P,0.001 vs. control,
#P,0.05 vs. pinch + Gal group,
##P,0.01 vs. pinch + Gal group,
###P,0.001 vs. pinch + Gal group.
doi:10.1371/journal.pone.0037621.g001
Figure 2. The thermal threshold alterations with different treatment from day 0 to day 24. The data are presented as means 6 SD (n=7).
*P,0.05 vs. control, **P,0.01 vs. control, ***P,0.001 vs. control,
#P,0.05 vs. pinch + Gal group,
##P,0.01 vs. pinch + Gal group,
###P,0.001 vs.
pinch + Gal group.
doi:10.1371/journal.pone.0037621.g002
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Gal protein levels increased significantly in DRG after sciatic
nerve-pinch injury at day 8, 16, and 24 as compared with that in
sham-operated control animals. Gal administration decreased Gal
protein levels in DRG after sciatic nerve-pinch injury at day 16
and 24, but not day 8, as compared with that in sciatic nerve-
pinched animals without Gal treatment at the same experimental
time point (Fig. 5A). Gal protein levels increased significantly in
SDH after sciatic nerve-pinch injury at day 8, 16, and 24 as
compared with that in sham-operated control animals. Gal
administration did not have significant effects on Gal protein
expression in SDH after sciatic nerve-pinch injury as compared
with that in sciatic nerve-pinched animals without Gal treatment
at the same experimental time point (Fig. 5B).
GalR1 protein levels decreased significantly in DRG after sciatic
nerve-pinch injury at day 8, 16, and 24 as compared with that in
sham-operated control animals. Gal administration decreased
GalR1 protein levels in DRG after sciatic nerve-pinch injury at
day 8, 16, and 24 as compared with that in sciatic nerve-pinched
animals without Gal treatment at the same experimental time
point (Fig. 5C). GalR1 protein levels increased significantly in
SDH after sciatic nerve-pinch injury at day 8, 16, and 24 as
compared with that in sham-operated control animals. Gal
administration decreased GalR1 protein levels in SDH after
sciatic nerve-pinch injury at day 8, 16, and 24 as compared with
that in sciatic nerve-pinched animals without Gal treatment and in
sham-operated control animals (Fig. 5D).
GalR2 protein levels increased significantly in DRG and SDH
after sciatic nerve-pinch injury at day 8, 16, and 24 as compared
with that in sham-operated control animals. Gal administration
did not have significant effects on GalR2 protein expression in
DRG and SDH after sciatic nerve-pinch injury as compared with
that in sciatic nerve-pinched animals without Gal treatment at the
same experimental time point (Fig. 5E, F).
Morphological alterations of nerve fiber in sciatic nerve
with toluidine blue staining
Most of the nerve fibers were undergoing some degree of
dystrophy after sciatic nerve-pinch injury at day 8 and 16. The
internal structure of the nerve was severely disorganized after
sciatic nerve-pinch injury at day 8 and 16. Most of the nerve fibers
showed recovery after sciatic nerve-pinch injury at day 24. The
dystrophy appearance improved at day 8 and 16 after sciatic
nerve-pinch injury with Gal treatment. Most of the nerve fibers
recovered to almost normal status at day 24 after sciatic nerve-
pinch injury with Gal treatment (Fig. 6).
Ultrastructural alterations of sciatic nerve
Myelinated axons degenerated to myelin debris and lost
axoplasm at day 8 and 16 after sciatic nerve-pinch injury. The
myelin and axoplasm were partially recovered at day 24 after
sciatic nerve-pinch injury. The axoplasm loss and myelin
breakdown at day 8 and 16 after sciatic nerve-pinch injury were
less severe in Gal treated animals as compared with that in sciatic
nerve-pinched animals without Gal treatment. The broken myelin
is recovering with clear layers and the lost axoplasm is recovered at
day 24 after sciatic nerve-pinch injury (Fig. 7).
Discussion
Treatment of chronic neuropathic pain resulted from peripheral
nerve injury is one of the most difficult problems in modern
clinical practice [25]. Current pharmacological treatments for
neuropathic pain are not able to prevent or revert morphological
and molecular consequences of tissue injury. On the other hand,
many neurotrophins coexist restorative effects with hyperalgesia
[1]. It has been shown that the neuropeptide Gal might have anti-
nociceptive role in inflammatory conditions as well as the
neurotrophic effects after nerve injury [17,21]. In the present
study, a dramatically upregulation of Gal in DRG and SDH
caused by sciatic nerve-pinch injury was observed. Exogenous Gal
Figure 3. The NCV alterations at different experimental
conditions. Panel A: MNCV decreased significantly after sciatic
nerve-pinch injury at day 16 and 24 as compared with that in sham-
operated control animals. Gal treatment improved MNCV significantly
at the same experimental time point. Panel B: SNCV decreased
significantly after sciatic nerve-pinch injury at day 16 and 24 as
compared with that in sham-operated control animals. Gal treatment
improved SNCV significantly at the same experimental time point. The
data are presented as mean 6 SD (n=7). *P,0.05, **P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0037621.g003
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injury induced neuropathic pain animal model. It is very
interesting that Gal, GalR1 and GalR2, which may play a key
role in pain regulation and nerve regeneration, show great
expression plasticity in DRG and SDH after nerve injury and
intrathecal injection of exogenous Gal. Morphological investiga-
tion displays a serious damage in the pinched nerve and a
facilitated regeneration after exogenous Gal treatment.
Mechanical injury of the sciatic nerve triggers numerous
biochemical events in DRG and SDH, which respond to the
neuropathic pain and nerve regeneration. A recent study with a
sciatic nerve injury rat model indicated that one of the most
Figure 4. Expression of mRNAs for Gal, GalR1, and GalR2 in DRG and SDH. Panel A: Gal mRNA levels in DRG after sciatic nerve-pinch injury
at day 8, 16, and 24 without or with Gal treatment. Panel B: Gal mRNA levels in SDH after sciatic nerve-pinch injury at day 8, 16, and 24 without or with
Gal treatment. Panel C: GalR1 mRNA levels in DRG after sciatic nerve-pinch injury at day 8, 16, and 24 without or with Gal treatment. Panel D: GalR1
mRNA levels in SDH after sciatic nerve-pinch injury at day 8, 16, and 24 without or with Gal treatment. Panel E: GalR2 mRNA levels in DRG after sciatic
nerve-pinch injury at day 8, 16, and 24 without or with Gal treatment. Panel F: GalR2 mRNA levels in SDH after sciatic nerve-pinch injury at day 8, 16,
and 24 without or with Gal treatment. The mRNA level was expressed as the ratio of control. The data are presented as mean 6 SD (n=7). *P,0.05,
**P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0037621.g004
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which will not return to normal until regeneration is complete
[26]. It has, therefore, been suggested that Gal may be involved in
the neuropathic pain regulation and nerve regeneration after
peripheral nerve injury. It is well widespread accepted that sensory
hypersensitivity followed by peripheral nerve injury is caused by
the hyper C-fiber activity and sensitization of CNS, especially in
SDH [27,28]. During intrathecal injection, the administered drugs
mainly diffuse directly into the superficial neurons in the SDH
[29]. The superficial layers (laminae I and II) of SDH receives
strong input from thin primary afferent fibers and is involved in
nociception, pain, temperature sensing and other experiences
[30,31]. In the present study, intrathecal injection of exogenous
Gal could ameliorate mechanical and thermal sensitization caused
by sciatic nerve-pinch injury.
The observed antinociceptive effects and neuronal trophic
effects of endogenous or exogenous Gal are likely mediated by the
activation of GalR1 and GalR2 which are expressed in DRG
neurons [32,33]. It is also found a high level of GalR1, but not
GalR2, expression in the interneurons of SDH. The levels of the
both receptor subtypes display a great adjustability under
difference situations [34]. Although the precise actions of Gal
and its receptor subtypes in nociception and the exact sites of
action have not yet been fully clarified, there is more and more
evidence indicates that Gal could interact with the morphine/
opioid receptor system and inhibit excited transmitter release to
act as analgesia [35–37]. This effect is thought to be mainly
mediated by GalR1 which is an inhibitory G-protein couple
receptor. However, the GalR2, an excitatory G-protein couple
receptor, is also proved to be a valid target in analgesia in CNS
and PNS in several recent studies [36,38]. Gal is expressed only at
low levels in a small number of small-sized DRG neurons and
mainly in lamina II neurons at normal condition and dramatically
upregulates after nerve injury. Electrophysiology and behavior
studies indicate that the physiological inhibitory role of Gal
becomes more functional after peripheral nerve injury [15,38].
This upregulation might be caused by lost connection between
primary afferent neurons and target tissues. Disruption of axonal
transport of neuronal trophic factors synthesized by peripheral
target tissues removes the restrictive effect on Gal expression
[39,40]. These remarkable changes coincide with the finding that
Gal acts as an important antinociceptive factor and neuronal
trophic factor for injured neurons [41]. All the above researches
indicate that Gal upregulation after peripheral nerve injury could
be considered as a transform of normal neuronal sensory
conduction state to a protection and regeneration one.
It has been demonstrated that nerve injury induces complex
plasticity of Gal, GalR1 and GalR2 expression in DRG and SDH
neurons, which play crucial role in neuropathic pain and nerve
regeneration [26,41]. In the present study, intrathecal injection of
exogenous Gal caused a significantly downregulation of endoge-
nous Gal in DRG. This change might be compensatory effect of
exogenous Gal. Besides the dramatically change and important
role of Gal after nerve injury, another very interesting question is
whether and how Gal receptors change in this condition. In the
present study, GalR1 expression was downregulated in DRG but
Figure 5. Expression of Gal, GalR1, and GalR2 in DRG and SDH.
Panel A1, A2: Gal protein levels in DRG after sciatic nerve-pinch injury at
day 8, 16, and 24 without or with Gal treatment. Panel B1, B2: Gal
protein levels in SDH after sciatic nerve-pinch injury at day 8, 16, and 24
without or with Gal treatment. Panel C1, C2: GalR1 protein levels in DRG
after sciatic nerve-pinch injury at day 8, 16, and 24 without or with Gal
treatment. Panel D1, D2: GalR1 protein levels in SDH after sciatic nerve-
pinch injury at day 8, 16, and 24 without or with Gal treatment. Panel
E1, E2: GalR2 protein levels in DRG after sciatic nerve-pinch injury at day
8, 16, and 24 without or with Gal treatment. Panel F1, F2: GalR2 protein
levels in SDH after sciatic nerve-pinch injury at day 8, 16, and 24 without
or with Gal treatment. Lane 1: pinch 8 d; Lane 2: pinch + Gal 8 d; Lane 3:
control 8 d; Lane 4: pinch 16 d; Lane 5: pinch + Gal 16 d; Lane 6: control
16 d; Lane 7: pinch 24 d; Lane 8: pinch + Gal 24 d; Lane 9: control 24 d.
The protein level was expressed as the ratio of control. The data are
presented as mean 6 SD (n=7). *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0037621.g005
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DRG and SDH after sciatic nerve-pinch injury at the same
experimental time point. Intrathecal injection of exogenous Gal
decreased GalR1 levels but did not influence GalR2 expression,
which coincide with our previous study in vitro [42]. The effect of
depression of GalR1 by exogenous Gal may be an activator/
receptor negative feedback just like the others receptor adaptive
reaction. GalR1 has been confirmed to predominately locate in
postsynaptic membrane [43]. Except inhibition of active neuro-
peptide release, activation of GalR1 may also reduce excitability of
glutamatergic interneurons in SDH, thus cause antinociception
[44]. The upregulation GalR1 in SDH makes this effect more
potent after nerve injury, which may emphasize the important role
of Gal in pain modulation in spinal level. In contrast to GalR1,
which only couple to Gi protein, GalR2 can also activate Gq/11
protein leading to more complex functions [45]. Many studies pay
close attention to neuroprotective and neuronal trophic effect of
Gal conducted by GalR2 [46,47]. In the present study, the GalR2
in DRG and SDH was upregulated, which makes the increasing
Gal acts as neurotrophin more effective. An increasing and a
relative independent expression of GalR2 in both DRG and SDH
seem to be protected mechanisms, considerated its important role
in nerve regeneration after nerve injury. Although it has been
reported that GalR2 reduce its mRNA after axotomy [48], this
difference may explain by the different model used here. Sciatic
nerve axotomy is a severe damage, and even caused DRG
neuronal death [49], but which can’t be found in nerve-pinched
animal model.
In the present study, neuronal trophic actions and nerve
regeneration function of exogenous Gal were investigated by
observation of MNCV, SNCV, toluidine blue staining and
ultrastructural alterations after nerve-pinch injury. The recovery
of NCV is responding to regeneration of motor and sensory fibers.
Intrathecal injection of exogenous Gal significantly accelerated the
functional recovery of limb as measured by MNCV and SNCV.
The toluidine blue staining and TEM analysis showed more
Figure 6. Semi-thin cross sections of sciatic nerve with toluidine blue staining. Panel A1, A2 and A3: The dystrophy appearance of nerve
fibers after sciatic nerve-pinch injury at day 8, 16, and 24, respectively. The internal structure of the nerve was severely disorganized, sometimes with
apparently enlarged nerve fibers (arrows) in Panel A1 or A2. Panel B1 and B2: The dystrophy appearance improved at day 8 and 16, respectively, after
sciatic nerve-pinch injury with Gal treatment as compared with that in Panel A1 and A2. Panel B3: Most of the nerve fibers recovered to almost normal
status at day 24 after sciatic nerve-pinch injury with Gal treatment. Panel C1, C2, and C3: Normal appearance of the sciatic nerve, with small and large
diameter myelinated fibers regularly distributed in sham-operated control animals at day 8, 16 and day 24, respectively, after sham operation. Scale
bar=10 mm.
doi:10.1371/journal.pone.0037621.g006
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with that in rats without exogenous Gal administration after nerve-
pinch injury. These morphological results further confirmed the
tonic trophic effect of exogenous Gal after nerve injury.
In conclusion, Gal, via acivition of GalR1 and/or GalR2, may
have neuoprotective effects in reducing neuropathic pain behav-
iors and improving nerve regeneration after nerve injury. These
findings imply that interference with Gal and its recepotr system
might be effective for neuropathic pain treatment. These data offer
a new point of view on the treatment of neuropathic pain as well as
the neuroprotective effects of Gal and its receptor signaling system.
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